Blood Utilization and Transfusion Reactions in Pediatric Patients Transfused with Conventional or Pathogen Reduced Platelets

Wade L. Schulz, Jacob McPadden, Eric Gehrie, Burak Bahar, Amit Gokhale, Rebecca Ross, Nathaniel Price, Bryan R. Spencer, Edward Snyder

Research output: Contribution to journalArticle

Abstract

Objectives: To assess the safety and efficacy of a Food and Drug Administration-approved pathogen-reduced platelet (PLT) product in children, as ongoing questions regarding their use in this population remain. Study design: We report findings from a quality assurance review of PLT utilization, associated red blood cell transfusion trends, and short-term safety of conventional vs pathogen-reduced PLTs over a 21-month period while transitioning from conventional to pathogen-reduced PLTs at a large, tertiary care hospital. We assessed utilization in neonatal intensive care unit (NICU) patients, infants 0-1 year not in the NICU, and children age 1-18 years (PED). Results: In the 48 hours after an index conventional or pathogen-reduced platelet transfusion, respectively, NICU patients received 1.0 ± 1.4 (n = 91 transfusions) compared with 1.2 ± 1.3 (n = 145) additional platelet doses (P =.29); infants 0-1 year not in the NICU received 2.8 ± 3.0 (n = 125) vs 2.6 ± 2.6 (n = 254) additional platelet doses (P =.57); and PEDs received 0.9 ± 1.6 (n = 644) vs 1.4 ± 2.2 (n = 673) additional doses (P <.001). Time to subsequent transfusion and red cell utilization were similar in every group (P >.05). The number and type of transfusion reactions did not significantly vary based on PLT type and no rashes were reported in NICU patients receiving phototherapy and pathogen-reduced PLTs. Conclusions: Conventional and pathogen-reduced PLTs had similar utilization patterns in our pediatric populations. A small, but statistically significant, increase in transfusions was noted following pathogen-reduced PLT transfusion in PED patients, but not in other groups. Red cell utilization and transfusion reactions were similar for both products in all age groups.

Original languageEnglish (US)
JournalJournal of Pediatrics
DOIs
StatePublished - Jan 1 2019

Fingerprint

Neonatal Intensive Care Units
Blood Transfusion
Blood Platelets
Pediatrics
Platelet Transfusion
Utilization Review
Safety
Erythrocyte Transfusion
Phototherapy
Tertiary Healthcare
United States Food and Drug Administration
Exanthema
Tertiary Care Centers
Population
Age Groups
Transfusion Reaction

Keywords

  • pathogen reduction
  • pediatric transfusion
  • transfusion safety

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Blood Utilization and Transfusion Reactions in Pediatric Patients Transfused with Conventional or Pathogen Reduced Platelets. / Schulz, Wade L.; McPadden, Jacob; Gehrie, Eric; Bahar, Burak; Gokhale, Amit; Ross, Rebecca; Price, Nathaniel; Spencer, Bryan R.; Snyder, Edward.

In: Journal of Pediatrics, 01.01.2019.

Research output: Contribution to journalArticle

Schulz, Wade L. ; McPadden, Jacob ; Gehrie, Eric ; Bahar, Burak ; Gokhale, Amit ; Ross, Rebecca ; Price, Nathaniel ; Spencer, Bryan R. ; Snyder, Edward. / Blood Utilization and Transfusion Reactions in Pediatric Patients Transfused with Conventional or Pathogen Reduced Platelets. In: Journal of Pediatrics. 2019.
@article{a564d537c1004e5fa35e12dc7dfdf949,
title = "Blood Utilization and Transfusion Reactions in Pediatric Patients Transfused with Conventional or Pathogen Reduced Platelets",
abstract = "Objectives: To assess the safety and efficacy of a Food and Drug Administration-approved pathogen-reduced platelet (PLT) product in children, as ongoing questions regarding their use in this population remain. Study design: We report findings from a quality assurance review of PLT utilization, associated red blood cell transfusion trends, and short-term safety of conventional vs pathogen-reduced PLTs over a 21-month period while transitioning from conventional to pathogen-reduced PLTs at a large, tertiary care hospital. We assessed utilization in neonatal intensive care unit (NICU) patients, infants 0-1 year not in the NICU, and children age 1-18 years (PED). Results: In the 48 hours after an index conventional or pathogen-reduced platelet transfusion, respectively, NICU patients received 1.0 ± 1.4 (n = 91 transfusions) compared with 1.2 ± 1.3 (n = 145) additional platelet doses (P =.29); infants 0-1 year not in the NICU received 2.8 ± 3.0 (n = 125) vs 2.6 ± 2.6 (n = 254) additional platelet doses (P =.57); and PEDs received 0.9 ± 1.6 (n = 644) vs 1.4 ± 2.2 (n = 673) additional doses (P <.001). Time to subsequent transfusion and red cell utilization were similar in every group (P >.05). The number and type of transfusion reactions did not significantly vary based on PLT type and no rashes were reported in NICU patients receiving phototherapy and pathogen-reduced PLTs. Conclusions: Conventional and pathogen-reduced PLTs had similar utilization patterns in our pediatric populations. A small, but statistically significant, increase in transfusions was noted following pathogen-reduced PLT transfusion in PED patients, but not in other groups. Red cell utilization and transfusion reactions were similar for both products in all age groups.",
keywords = "pathogen reduction, pediatric transfusion, transfusion safety",
author = "Schulz, {Wade L.} and Jacob McPadden and Eric Gehrie and Burak Bahar and Amit Gokhale and Rebecca Ross and Nathaniel Price and Spencer, {Bryan R.} and Edward Snyder",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jpeds.2019.01.046",
language = "English (US)",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Blood Utilization and Transfusion Reactions in Pediatric Patients Transfused with Conventional or Pathogen Reduced Platelets

AU - Schulz, Wade L.

AU - McPadden, Jacob

AU - Gehrie, Eric

AU - Bahar, Burak

AU - Gokhale, Amit

AU - Ross, Rebecca

AU - Price, Nathaniel

AU - Spencer, Bryan R.

AU - Snyder, Edward

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: To assess the safety and efficacy of a Food and Drug Administration-approved pathogen-reduced platelet (PLT) product in children, as ongoing questions regarding their use in this population remain. Study design: We report findings from a quality assurance review of PLT utilization, associated red blood cell transfusion trends, and short-term safety of conventional vs pathogen-reduced PLTs over a 21-month period while transitioning from conventional to pathogen-reduced PLTs at a large, tertiary care hospital. We assessed utilization in neonatal intensive care unit (NICU) patients, infants 0-1 year not in the NICU, and children age 1-18 years (PED). Results: In the 48 hours after an index conventional or pathogen-reduced platelet transfusion, respectively, NICU patients received 1.0 ± 1.4 (n = 91 transfusions) compared with 1.2 ± 1.3 (n = 145) additional platelet doses (P =.29); infants 0-1 year not in the NICU received 2.8 ± 3.0 (n = 125) vs 2.6 ± 2.6 (n = 254) additional platelet doses (P =.57); and PEDs received 0.9 ± 1.6 (n = 644) vs 1.4 ± 2.2 (n = 673) additional doses (P <.001). Time to subsequent transfusion and red cell utilization were similar in every group (P >.05). The number and type of transfusion reactions did not significantly vary based on PLT type and no rashes were reported in NICU patients receiving phototherapy and pathogen-reduced PLTs. Conclusions: Conventional and pathogen-reduced PLTs had similar utilization patterns in our pediatric populations. A small, but statistically significant, increase in transfusions was noted following pathogen-reduced PLT transfusion in PED patients, but not in other groups. Red cell utilization and transfusion reactions were similar for both products in all age groups.

AB - Objectives: To assess the safety and efficacy of a Food and Drug Administration-approved pathogen-reduced platelet (PLT) product in children, as ongoing questions regarding their use in this population remain. Study design: We report findings from a quality assurance review of PLT utilization, associated red blood cell transfusion trends, and short-term safety of conventional vs pathogen-reduced PLTs over a 21-month period while transitioning from conventional to pathogen-reduced PLTs at a large, tertiary care hospital. We assessed utilization in neonatal intensive care unit (NICU) patients, infants 0-1 year not in the NICU, and children age 1-18 years (PED). Results: In the 48 hours after an index conventional or pathogen-reduced platelet transfusion, respectively, NICU patients received 1.0 ± 1.4 (n = 91 transfusions) compared with 1.2 ± 1.3 (n = 145) additional platelet doses (P =.29); infants 0-1 year not in the NICU received 2.8 ± 3.0 (n = 125) vs 2.6 ± 2.6 (n = 254) additional platelet doses (P =.57); and PEDs received 0.9 ± 1.6 (n = 644) vs 1.4 ± 2.2 (n = 673) additional doses (P <.001). Time to subsequent transfusion and red cell utilization were similar in every group (P >.05). The number and type of transfusion reactions did not significantly vary based on PLT type and no rashes were reported in NICU patients receiving phototherapy and pathogen-reduced PLTs. Conclusions: Conventional and pathogen-reduced PLTs had similar utilization patterns in our pediatric populations. A small, but statistically significant, increase in transfusions was noted following pathogen-reduced PLT transfusion in PED patients, but not in other groups. Red cell utilization and transfusion reactions were similar for both products in all age groups.

KW - pathogen reduction

KW - pediatric transfusion

KW - transfusion safety

UR - http://www.scopus.com/inward/record.url?scp=85062918852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062918852&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2019.01.046

DO - 10.1016/j.jpeds.2019.01.046

M3 - Article

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

ER -